Percutaneous coronary intervention (PCI) by drug-eluting stent (DES) may be useful in patients with acute myocardial infarction, however long-term safety issue should be solved. On-line registry of acute myocardial infarction at the web site of www.kamir.or.kr has been performed in 41 primary percutaneous coronary intervention (PCI) centers in Korea. Between November 2005 and June 2006, 1,541 patients who were implanted Cypher짰 or Taxus짰 stents, enrolled in Korea Acute Myocardial Infarction Registry (KAMIR) and discharged from hospital without death, were analyzed during 6-month clinical follow-up. There were two groups: group I [834 patients, 61.9짹11.9 years: Sirolimus-Eluting Stent (Cypher짰)], group II [707 patients, 62.9짹12.0 years: Paclitaxel-Eluting Stent (Taxus짰)]. The proportion of male was higher in group I (group I: group II=626 (75.1%):497 (70.3%), p=0.039) and diabetes was more common in group I (group I: group II=223 (26.7%):157 (22.2%), p=0.044). The target coronary artery was different between the 2 groups [group I – left main (LM):left anterior descending artery (LAD):left circumflex artery (LCX):Right coronary artery (RCA)=17(2.0%):461(55.3%):116(13.9%):240(28.8%), group II–LM:LAD:LCX:RCA=10(1.4%):322(45.5%):120(17.0%):255(36.1%)]. One month and six months major adverse cardiac events (MACE) were not significantly different between two groups. There were 17 stent thrombosis but, the incidence of stent thrombosis was not significantly different between two groups (group I: group II=9 (1.1%):8 (1.1%), p=1.000). The stent type, length, number, lesion complexity and diabetes were not significant for the incidence of MACE and stent thrombosis after adjustment. In conclusion, though Cypher짰 stent was more commonly used in LAD disease and diabetic patients, MACE and stent thrombosis were not different between two types of DES in KAMIR. DES can be used in patients with acute myocardial infarction with relatively low 6-month MACE rate.